Compare NOTV & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOTV | GDTC |
|---|---|---|
| Founded | 1974 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 24.8M |
| IPO Year | 1997 | 2023 |
| Metric | NOTV | GDTC |
|---|---|---|
| Price | $0.70 | $1.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 79.1K |
| Earning Date | 02-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $513,024,000.00 | $573,193.00 |
| Revenue This Year | $6.26 | $5.37 |
| Revenue Next Year | $45.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 4.54 | ★ 63.03 |
| 52 Week Low | $0.66 | $1.50 |
| 52 Week High | $6.48 | $4.05 |
| Indicator | NOTV | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 31.90 | 37.67 |
| Support Level | $0.79 | $1.71 |
| Resistance Level | $0.86 | $1.68 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 7.66 | 15.32 |
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.